Echosens developed the LHM™ to provide a digital solution with an ecosystem to support clinical decisions for physicians.
Patient management
Scores Calculators
Enhancing FibroScan® liver disease assessment with biological markers.
Additional tools and resources
The LHM platform is currently available only in the United States and some European countries. You can contact us to know more.
The FibroScan® device (Models: 530 Compact, 430 Mini+ and 630 Expert) is intended to measure liver stiffness (E) using Vibration Controlled Transient Elastography (VCTE®) at 50 Hz shear wave frequency and liver ultrasound attenuation coefficient (CAP)* at 3.5 MHz. FibroScan® 630 Expert is also intended to measure spleen stiffness using VCTE® at 100 Hz shear wave frequency. FibroScan liver stiffness measurements (LSM) by VCTE® may aid the physician in determining the likelihood of cirrhosis and may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of liver fibrosis. FibroScan CAP measurements may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of hepatic steatosis. FibroScan® is indicated as a non-invasive aid for the clinical management, diagnosis, and monitoring of adult and pediatric patients with confirmed or suspected liver disease, as part of an overall assessment of the liver. Results in the pediatric population should be interpreted while considering the clinical condition and the overall patient profile. The FibroScan® device is intended for use by healthcare professionals in hospitals, clinics or any facility where healthcare is provided. *CAP refers to ultrasound attenuation coefficient (originally defined as Controlled Attenuation Parameter). CAP on S+ probe is only available with SmartExam capability. FibroScan Gateway is a Non-Device Medical Device Data Systems (MDDS) and Interpretation Guide (available on myFibroScan application) is a Non-Device Clinical Decision Support (CDS) that meet the criteria outlined in section 520(o) (1)(E) of the FD&C Act. According to the Federal Food, Drug, and Cosmetic Act (21 CFR 880.6310). Fast, Agile 3+ and Agile 4 Products are registered class 1 devices (FDA). Fast calculator is a tool for clinicians, computed from LSM and CAP (obtained from FibroScan® device) and AST blood parameter measurement, to aid in the identification of a patient with suspicion of NAFLD as being at risk for active fibrotic NASH (NASH+NAS≥4+F≥2). It was developed based on a prospective multicenter cohort and published in peer-reviewed literature. Agile 3+ calculator is a tool for clinicians, computed from LSM (obtained from FibroScan® device), AST, ALT, platelets, diabetes status, age and gender, to aid in the identification of patients with suspicion of NAFLD as having advanced fibrosis. It was developed based on a pool of retrospective cohorts and published in peer-reviewed literature. Agile 4 calculator is a tool for clinicians, computed from LSM (obtained from FibroScan device), AST, ALT, platelets, diabetes status and gender, to aid in the identification of patients with suspicion of NAFLD as having cirrhosis. It was developed based on a pool of retrospective cohorts and published in peer-reviewed literature. Fast, Agile 3+ and Agile 4 are presented as educational services intended for licensed healthcare professionals. While these scores are about specific medical and health issues,they are not a substitute for or a replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.